Skip to main content
CLOV
NASDAQ Finance

Clover Health Secures 4.5-Star Medicare Rating for 97% of Members After Court Order

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Financial
Sentiment info
Positive
Importance info
9
Price
$4.24
Mkt Cap
$2.259B
52W Low
$1.58
52W High
$4.44
52W Position info
168% above low
Off High info
4.5% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

CLOV has more than doubled off its 52-week low of $1.58 on elevated volume (2.3× avg).

Summary

Clover Health's primary Medicare plan, covering over 97% of its members, has been upgraded to a 4.5-star rating by CMS following a successful lawsuit, significantly boosting its future revenue prospects.


Key Events · Corporate Governance and Compliance · CLOV

  • Major Star Rating Upgrade

    CMS has recalculated Clover's 2026 Star Rating for Contract H5141 (PPO plan), which covers over 97% of its members, from 3.5 stars to 4.5 stars.

  • Court-Ordered Recalculation

    The upgrade was mandated by a U.S. District Court, which granted summary judgment to Clover and ordered CMS to recalculate the rating.

  • Significant Financial Impact

    The higher 4.5-star rating directly impacts Payment Year 2027, leading to increased payments from CMS and improved marketability for the company's primary plan.


Analysis · CLOV · Finance

Clover Health's primary Medicare plan, covering over 97% of its members, has been upgraded from a 3.5-star to a 4.5-star rating by the Centers for Medicare & Medicaid Services (CMS). This significant upgrade, which impacts Payment Year 2027, resulted from a successful lawsuit where a U.S. District Court ordered CMS to recalculate the rating. A higher Star Rating directly translates to increased payments from CMS and enhances the company's ability to attract and retain members, providing a substantial boost to future revenue. This positive development builds on the company's recent achievement of its first-ever positive GAAP Net Income in Q1 2026 and comes as the stock is trading near its 52-week high, reflecting strong operational momentum.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLOV was trading at $4.24 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.58 to $4.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLOV - Latest Insights

CLOV
Nov 06, 2026, 8:03 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $3.73 info
Change: -$0.7202 (-16%) info
Market Cap: $1.973B info
CLOV
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.67
Real-time Price: $3.73 info
Change: -$0.940 (-20%) info
Market Cap: $1.973B info
CLOV
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $3.73 info
Change: -$0.980 (-21%) info
Market Cap: $1.973B info
CLOV
Oct 08, 2026, 6:45 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $3.73 info
Change: -$1.27 (-25%) info
Market Cap: $1.973B info
CLOV
Aug 07, 2026, 8:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.69
Real-time Price: $3.73 info
Change: -$0.960 (-20%) info
Market Cap: $1.973B info